A Meta-Narrative Review of RUNX1-RUNX1T1 and its Relativity to CBF Disruption Within the Adult Population
Research Methods Poster Sessions
2023
- 251Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage251
- Downloads199
- Abstract Views52
Conference Paper Description
Acute Myeloid Leukemia (AML) is an aggressive subgroup of leukemias developed from a deviant hematopoietic stem cell, prevented from differentiating into a mature cell. Additionally, core binding factor (CBF) is disrupted by the translocation of chromosomes 8 and 21. This balanced translocation generates the RUNX1-RUNX1T1 fusion gene on the derivative chromosome 8, resulting in t(8;21)(q22;q22.1). These events cause a blockage of hematopoietic stem cell differentiation and ultimately lead to leukemia transformation (Beghini, A. 2019). Using Fluorescence in situ hybridization (FISH) and Karyotyping, molecular translocation can be detected, visualized, and associated with chromosomes 8 and 21 [t(8;21)(q22;q22)]. Furthermore, this study will investigate how gene fusion and translocation disrupt CBF for the purpose of understanding how AML is diagnosed and treatment. To address this, we conducted a meta-narrative review of the number of articles that correspond to each sub-theme of the approach to AML in the context of RUNX1-RUNX1T1 fusion gene, including the utilization of treatments, its detail on correlation to CBF complex, how the research method was depicted, limitations, audience, technology, and treatment. One of the most important aspects of the study was the understanding of genetic abnormalities and the use of genetic analysis in developing future treatment strategies for leukemia. The correlation of RUNX1-RUNX1T1 gene generated on the derivative chromosome 8 will result in t(8;21)(q22;q22.1), a balanced translocation.
Bibliographic Details
UT MD Anderson Cancer Center Research Medical Library
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know